OBJECTIVE: We show our experience with test of 70 genes (Mammaprint®), in evaluation and the treatment patients with breast cancer, we evaluated the (Target Print) microarray expression level of estrogen receptor, progesterone receptor and HER2 compared with immunohistochemistry. METHOD: 66 patients with breast cancer were evaluated in the breast cancer Unit Leopoldo Aguerrevere, with clinical stage I-II, and node negative, with Mammaprint® test and Target Print, who were to mastectomy or conservative surgery and sentinel node. RESULTS: 66 patients 86 % was treated by conservative surgery and the sentinel node. 46.9 % were node-positive including 3 micro-metastases (4.5 %). Hormone receptors were expressed as positive for estrogen and progesterone in 63 % the concordance between microarray and immunohistochemistry was 79 %. Two patients were discordant for HER2 receptor (3 %) what shows high concordance between both methods. Additional FISH was used in these cases; they were concordant with microarray analysis (Target Print). 66 patients, 42 (64 %) were classified as high genetic risk, indication of chemotherapy in spite of what established the pathological clinical factors. 24 patients (36 %) were classified as low risk considered pathological and clinical factors besides Mammaprint® to indicated adjuvant therapy. CONCLUSION: Mammaprint® genetic testing is a tool of high utility, to complement the decision of adjuvant treatment in patients with breast cancer. The microarray analysis (Target Print) shows high concordance with immunohistochemistry/FISH and provides an additional objective assessment of tumor receptor status in breast cancer

Author Name: CLAUDIA GONZÁLEZ CANELÓN, GERARDO HERNÁNDEZ MUÑOZ, RICARDO PAREDES HANY, JUAN HERNÁNDEZ RASQUÍN, CARMEN ELENA MARÍN

URL: View PDF

Keywords: Breast, cancer, gene expression, profile of 70 genes.

ISSN: 2343-6239

EISSN: ppi201402DC4478

EOI/DOI:

Add Citation Views: 3259

---